Qiagen NVXTER:QIA -1.94%74 Interest Coverage is 10.55 as of Mar. 2026, which is 67% above its 10-year median of 6.30. GuruFocus rates XTER:QIA with a GF Score™ of 74/100 and a GF Value™ of €45.70 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 94 Medical Diagnostics & Research companies, Qiagen NV ranks better than 55.32% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Qiagen NV's
Operating Income
for the
three
months ended in Mar. 2026 was €101 Mil. Qiagen NV's Interest Expense for the
three
months ended in Mar. 2026 was €-10 Mil.
Qiagen NV's interest coverage for the quarter that ended in Mar. 2026 was 10.55.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Qiagen NV's Interest Coverage or its related term are showing as below:
XTER:QIA'
s Interest Coverage Range Over the Past 10 Years
Min: 2.53 Med: 6.3 Max: 15.65
Current: 13.83
XTER:QIA's Interest Coverage is ranked better than 55.32% of 94
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.155
vs XTER:QIA: 13.83
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Qiagen NV Interest Coverage Related Terms
Qiagen NV Interest Coverage Historical Data
* Premium members only.
The historical data trend for Qiagen NV's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XTER:QIA vs TWST, CRL, BLLN: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Qiagen NV's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qiagen NV Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Qiagen NV's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (XTER:QIA) has a Interest Coverage of 10.55 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Qiagen NV and its competitors. This is 67% above median its historical median of 6.30. Over the past decade, Qiagen NV's Interest Coverage has ranged from 2.53 to 15.65. According to the industry distribution chart, Qiagen NV ranks #42 out of 94 companies in the Medical Diagnostics & Research industry, placing it in the top 44.7%.
Is Qiagen NV's Interest Coverage too high?
Qiagen NV's current Interest Coverage of 10.55 is 67% above median its 10-year median of 6.30. Over the past 10 years, this metric has ranged from a low of 2.53 to a high of 15.65. The Medical Diagnostics & Research industry median Interest Coverage is 9.16. Qiagen NV's value of 10.55 is 15.2% above this industry median. Based on the distribution chart, Qiagen NV ranks #42 out of 94 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Qiagen NV has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Interest Coverage compare to TWST and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #42 out of 94 companies for Interest Coverage. This puts Qiagen NV in the upper half of its industry. The industry median Interest Coverage is 9.16. Qiagen NV's value of 10.55 is 15.2% above this benchmark. Historically, Qiagen NV's own Interest Coverage has ranged from 2.53 to 15.65 over the past decade. While the company's 10-year median is 6.30 vs. the industry median of 9.16, Qiagen NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.16, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qiagen NV's current Interest Coverage of 10.55 is 15.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Qiagen NV and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qiagen NV's current Interest Coverage is 10.55, which is 67% above median its own 10-year median of 6.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.70, compared to a current price of €33.90 — trading 25.8% below its estimated fair value. The current Interest Coverage is 10.55, which is 67% above median its 10-year median of 6.30 and 15.2% above the Medical Diagnostics & Research industry median of 9.16. Qiagen NV's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current Interest Coverage is 10.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (XTER:QIA) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of €33.90 is trading 25.8% below its estimated GF Value™ of €45.70.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for XTER:QIA:
Interest Coverage: 10.55 (67% above median its 10-year median of 6.30)
GF Value™: €45.70 vs. price of €33.90 (25.8% below fair value)
Industry Position: 15.2% above the Medical Diagnostics & Research median (#42 of 94)
No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
74GF Score
Get the complete analysis for XTER:QIA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:QIA has been successfully added to your 
